BTG (OTCMKTS:BTGGF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday.

According to Zacks, “BTG plc is a healthcare company. Its operating segment consists of Interventional Medicine and Specialty Pharmaceuticals. Interventional Medicine offers treatment of cancer, severe emphysema, severe blood clots and varicoseveins. Specialty Pharmaceuticals helps patients overexposed to certain medications or toxins. BTG plc is headquartered in London, the United Kingdom. “

Shares of BTG (OTCMKTS BTGGF) remained flat at $$9.91 during midday trading on Tuesday. BTG has a fifty-two week low of $6.74 and a fifty-two week high of $10.04.

COPYRIGHT VIOLATION WARNING: This report was first reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/12/19/btg-btggf-downgraded-by-zacks-investment-research-to-sell.html.

Get a free copy of the Zacks research report on BTG (BTGGF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.